Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01381562 · ClinicalTrials.gov registry record · Phase 2
GSK2251052 in the Treatment of Complicated Intra-abdominal Infections
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01381562 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 15 participants.
The verdict
NCT01381562, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections. GSK2251052 will be compared to meropenem, an IV therapy that is approved for use in the treatment of subjects with cIAI. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cIAI.
Interventions
- OTHER Placebo
- DRUG Meropenem
- DRUG Drug: GSK2251052
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-10-03 |
| Est. Completion | 2012-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01381562
The ClinicalTrials.gov registry entry for NCT01381562 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01381562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01381562 about?
NCT01381562 is a clinical study titled "GSK2251052 in the Treatment of Complicated Intra-abdominal Infections". This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections. GSK2251052 will be compared to meropenem, an IV therapy that is approved for use in the treatment of subjects with cIAI. GSK2251...
What is the current status of trial NCT01381562?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2011-10-03. Estimated completion is 2012-03-05.
What interventions are being tested in trial NCT01381562?
The interventions under investigation include: Placebo (OTHER), Meropenem (DRUG), Drug: GSK2251052 (DRUG).
Who is sponsoring clinical trial NCT01381562?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.